Long Femoropopliteal Lesions Challenge the Limits of Endovascular Technique: Contemporary Systematic Review and Meta-analysis

长段股腘动脉病变挑战血管内治疗技术的极限:当代系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Traditionally, patients with symptomatic femoropopliteal artery occlusive disease have been treated surgically. However, a growing body of clinical evidence has emerged supporting endovascular treatment in patients with long lesions. The objective of this systematic search and meta-analysis was to assess contemporary outcomes in patients undergoing endovascular treatment for long femoral-popliteal lesions. METHODS: An updated systematic search of Embase, including MEDLINE, identified relevant records published between January 2000 and March 2023 reporting a minimum of 1-year follow-up of endovascular revascularization in patients with mean lesion length ≥20 cm. A pooled meta-analysis was performed using a random-effects model for all longitudinal cumulative event rates. Subgroup analyses explored stratification by lesion length, intervention, study design, and outcome definition. Quality of evidence and risk of bias assessments were conducted. RESULTS: A total of 28 records, 2338 limbs, and 2311 patients, were analyzed. The pooled cumulative event rates (95% CI) for primary patency were as follows: 0.85 (95% CI, 0.81-0.89), 0.67 (95% CI, 0.61-0.73), 0.48 (95% CI, 0.38-0.57), and 0.42 (95% CI, 0.33-0.52); secondary patency: 0.90 (95% CI, 0.85-0.93), 0.84 (95% CI, 0.77-0.89), 0.72 (95% CI, 0.64-0.78), 0.63 (95% CI, 0.52-0.73); and freedom from target lesion revascularization: 0.93 (95% CI, 0.89-0.96), 0.79 (95% CI, 0.74-0.83), 0.68 (95% CI, 0.62-0.73), and 0.63 (95% CI, 0.57-0.69) at 6, 12, 24, and 36 months, respectively. Select subgroup analyses showed clinically relevant variation in event rates. CONCLUSIONS: This systematic search and meta-analysis provides important insight into the performance of endovascular revascularization in patients with long lesions. These findings will need to be considered as treatment decisions are made.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。